Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Tocilizumab
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Tocilizumab 200mg/10ml solution for infusion vials
1001030W0AAABAB
|
Tocilizumab | Tocilizumab | Musculoskeletal and Joint Diseases | 2 |
|
Tocilizumab 400mg/20ml solution for infusion vials
1001030W0AAACAC
|
Tocilizumab | Tocilizumab | Musculoskeletal and Joint Diseases | 1 |
|
RoActemra 162mg/0.9ml inj pre-filled syringes
1001030W0BBADAD
|
Roactemra | Tocilizumab | Musculoskeletal and Joint Diseases | No data available |
|
RoActemra 162mg/0.9ml solution for injection pre-filled pens
1001030W0BBAEAE
|
Roactemra | Tocilizumab | Musculoskeletal and Joint Diseases | No data available |
|
RoActemra 200mg/10ml concentrate for inf vials
1001030W0BBABAB
|
Roactemra | Tocilizumab | Musculoskeletal and Joint Diseases | No data available |
|
RoActemra 400mg/20ml concentrate for inf vials
1001030W0BBACAC
|
Roactemra | Tocilizumab | Musculoskeletal and Joint Diseases | No data available |
|
RoActemra 80mg/4ml concentrate for inf vials
1001030W0BBAAAA
|
Roactemra | Tocilizumab | Musculoskeletal and Joint Diseases | No data available |
|
Tocilizumab 162mg/0.9ml inj pre-filled disposable devices
1001030W0AAAEAE
|
Tocilizumab | Tocilizumab | Musculoskeletal and Joint Diseases | No data available |
|
Tocilizumab 162mg/0.9ml inj pre-filled syringes
1001030W0AAADAD
|
Tocilizumab | Tocilizumab | Musculoskeletal and Joint Diseases | No data available |
|
Tocilizumab 80mg/4ml solution for infusion vials
1001030W0AAAAAA
|
Tocilizumab | Tocilizumab | Musculoskeletal and Joint Diseases | No data available |
|
Tyenne 162mg/0.9ml inj pre-filled syringes
1001030W0BCAAAD
|
Tyenne | Tocilizumab | Musculoskeletal and Joint Diseases | No data available |
|
Tyenne 162mg/0.9ml solution for injection pre-filled pens
1001030W0BCABAE
|
Tyenne | Tocilizumab | Musculoskeletal and Joint Diseases | No data available |
|
Tyenne 200mg/10ml concentrate for inf vials
1001030W0BCADAB
|
Tyenne | Tocilizumab | Musculoskeletal and Joint Diseases | No data available |
|
Tyenne 400mg/20ml concentrate for inf vials
1001030W0BCACAC
|
Tyenne | Tocilizumab | Musculoskeletal and Joint Diseases | No data available |
|
Tyenne 80mg/4ml concentrate for solution for infusion vials
1001030W0BCAEAA
|
Tyenne | Tocilizumab | Musculoskeletal and Joint Diseases | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.